---
title: "新药组合延长肺癌生存期"
description: "新药组合延长肺癌生存期"
image: https://image.informedainews.com/2024/10/Hea-6u9-1728128868-0.jpg
---


:::info

“智闻AI“ 是由人工智能编撰的刊物集合，确保您只获得最有价值的信息，旨在助您消除信息差，突破信息茧房的局限。  [了解更多 >>](/)

:::

# 新药组合延长肺癌生存期

import Tabs from '@theme/Tabs';
import TabItem from '@theme/TabItem';

<Tabs
	defaultValue="summary"
	values={[
	{label: 'summary', value: 'summary'},
	{label: 'score', value: 'score'},
]}>
<TabItem value="summary">
<img
  src="https://image.informedainews.com/2024/10/Hea-6u9-1728128868-0.jpg"
  alt="New Drug Combo Extends Lung Cancer Survival"
/>



医生们正在庆祝一种新药组合，这种组合将肺癌进展减缓了比标准治疗长40%的时间。肺癌每年导致180万人死亡。晚期病例的情况更糟。

在全球试验中，患有晚期非小细胞肺癌（NSCLC）和EGFR突变的患者——这在女性和轻度吸烟者中很常见——在接受amivantamab和lazertinib治疗后，疾病进展前存活了23.7个月。标准治疗osimertinib提供了16.6个月。

Amivantamab是一种单克隆抗体；lazertinib是一种酪氨酸激酶抑制剂。两者都针对癌细胞。将它们结合使用提高了生存率。FDA于八月批准了这种组合。在英国的可用性取决于NHS的认可。

副作用包括皮疹、感染和血栓。精准医学，根据基因特征定制治疗方案，推动了这些进展。

Roy Castle肺癌基金会的Paula Chadwick称新治疗为“希望的火箭燃料”。Cancer Research UK的Anna Kinsella看到了癌症研究的“黄金时代”，改善了生活并减少了恐惧。
</TabItem>
<TabItem value="score">
	| Scores     | Value   | Explanation |
	| -------- | ------- | ------- |
	| Objectivity  | 6    | Comprehensive reporting with in-depth analysis.    |
	| Social Impact | 5     | Significantly influences public opinion.    |
	| Credibility    | 6    | Verified independently by multiple sources.    |
	| Potential    | 6    | Almost inevitably leads to significant changes.    |
	| Practicality    | 5    | Widely applied in practice with good results.    |
	| Entertainment Value    | 2    | Includes a few entertaining elements.    |
</TabItem>
</Tabs>

[Full article>>](https://www.theguardian.com/society/2024/oct/04/amazing-trial-shows-drug-combination-stops-lung-cancer-advancing-for-longer)
